BriaCell Therapeutics (BCT) Q4 2024 earnings summary

Executive summary

• Clinical-stage biotech focused on immunotherapies for cancer, advancing Bria-IMT™ in pivotal Phase 3 for metastatic breast cancer under FDA Fast Track designation, with promising Phase 2 results showing median overall survival of 13.4–15.6 months, outperforming historical controls.

• Expanded pipeline includes Bria-OTS™ (off-the-shelf personalized immunotherapy) and Bria-PROS+™ for prostate cancer, with positive pre-IND FDA feedback and new clinical collaborations.

• Recent financings raised $13.5M in September and October 2024 to support ongoing trials and operations.

Financial highlights

• Fiscal year ended July 31, 2024: Research and development expenses rose to $27.2M (from $15.3M in 2023), driven by expanded clinical trials and preclinical programs.

• General and administrative expenses decreased to $6.2M (from $7.9M in 2023), reflecting cost controls.

• Net loss for the year was $4.8M, a significant improvement from $20.3M in 2023, mainly due to a $28.2M gain from the change in fair value of warrant liability.

• Cash and cash equivalents at year-end were $0.86M, down from $21.3M, with negative working capital of $3.8M and an accumulated deficit of $85.4M.

Outlook and guidance

• Management continues to focus resources on the pivotal Phase 3 Bria-IMT™ study and expects to seek additional capital to fund operations.

• Expanded access policy authorized by FDA for Bria-IMT™ in metastatic breast cancer.

• IND filings for new immunotherapy cell lines anticipated in 2025.